Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Healthcare Biotechnology
Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Trillium Therapeutics Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Post by DollarMasteron Feb 22, 2012 12:24pm
315 Views
Post# 19567203

ot) 2x NDA filing+ Profitability in 2012 (Mcap 24

ot) 2x NDA filing+ Profitability in 2012 (Mcap 24

BIG PARTNERSHIPS NEWS THIS Q + PROFITABILITY IN THIS YEAR = A LIFETIME OPPORTUNITY HERE .THE MOST INVESTORS STILL NOT REALIZE THE POTENTIAL IN THIS LOW FLOAT MONSTER .GLTA


Partnership news THIS Q and 2 new NDA filings later this year !!!
9 drugs in Pipeline including a Blockbuster all these drugs will be on the Market within 2-3 years !

Burn rate is only 1.2 M a year = cash untill late 2015 EXCLUDING upfront payments from upcoming Partnerships and EXCLUDING cpi-300 revenue.

Price Target : $3-5 within 12-18 Months ! Please do your own DD and realize the MONSTER POTENTIAL in this Goldmine !


Intelgenx (IGX.V)

Market Cap : $ 23.1 M
Cash: $ 4.3 M
Price : 0.50 $


NO DEBT

Shares Out : 45 M ( 23 M shares are held by Insiders + Institutions)


HEAVY BUYING BY INSTITUTIONS
https://data.cnbc.com/quotes/IGXT.OB/tab/8


Burn-rate only 300K per Q / IGXT has 4.3 M cash / Do the Math !
https://images.investorshub.advfn.com/images/uploads/2012/1/11/yimmbslide0004_image006.jpg



PARTNERDEAL THIS QUARTER
https://images.investorshub.advfn.com/images/uploads/2012/1/11/wliylslide0009_image018.jpg


Sales Potential for approved drug CPI-300
https://images.investorshub.advfn.com/images/uploads/2012/1/11/tzofmslide0008_image016.jpg


Profitability and 2 new NDA filings in 2012
https://images.investorshub.advfn.com/images/uploads/2012/1/11/bnavdslide0018_image036.jpg


MONSTER PIPELINE including a Blockbuster
https://images.investorshub.advfn.com/images/uploads/2012/1/11/hksavslide0006_image012.jpg


Biomedreport Article from Nov 2011
https://www.biomedreports.com/2011111183312/fda-spproval-is-a-game-changer-for-intelgenx.html

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities